Previous studies have shown that linsitinib has anti-tumor activity and acceptable tolerability in patients with adrenocortical adenocarcinoma, so researchers sought to compare its efficacy versus placebo in patients with advanced adrenocortical carcinoma.

For the international, double-blind, placebo-controlled phase 3 study, researchers enrolled 139 patients with advanced adrenocortical carcinoma, a rare, aggressive cancer that lacks many treatment options, and assigned 90 of whom to linsitinib and 49 to placebo. Patients in the linsitinib group received linsitinib 150mg orally twice daily.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.